Ijantkar, senior principal scientist, CMC team lead, cell and gene therapies at Bristol Myers Squibb, shares her experiences and provides his advice on how cell therapy companies can develop better flow cytometry assay strategies for cell therapies, including: (1) What is/isn’t phase appropriate; (2) Understanding regulatory implications; (3) FMO controls - why you need them; (4) Qualification attributes – How many experiments is enough

свернуть